Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected women from South Africa, Brazil and Botswana

Journal of Clinical Virology

Volumn 52, Issue 3, 2011, Pages 265-268

  Firnhaber, C ^a,b   Evans, D ^a   Friedman Khalili, R ^c   Willliams, S ^b   Michelow, P ^a,d   Matlhagela, K ^e,f   Wester, C ^f   Grinsztejn, B ^c   Lockman, S ^f,g  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b RIGHT TO CARE   (South Africa)

^c Funda??o Oswaldo Cruz   (Brazil)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e UNIVERSITY OF BOTSWANA   (Botswana)

^f BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

HIV; HPV serology; Resource limited countries

Indexed keywords

VIRUS ANTIBODY; VIRUS RNA;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BOTSWANA; BRAZIL; CD4 LYMPHOCYTE COUNT; EDUCATIONAL STATUS; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEROPREVALENCE; SEROTYPE; SEROTYPING; SOUTH AFRICA; UTERINE CERVIX CANCER; VIRUS LOAD;

ADULT; ANTIBODIES, VIRAL; BOTSWANA; BRAZIL; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RNA, VIRAL; SEROEPIDEMIOLOGIC STUDIES; SOUTH AFRICA;

EID: 80054702665     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.08.011     Document Type: Article

References (17)

1. International Agency for Research on Cancer WHO. [accessed 14.03.2011]. http://globocan.iarc.fr/.
2. Firnhaber C., Van Le H., Pettifor A., Schulze D., Michelow P., Sanne I., et al. Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg, South Africa. Cancer Causes Control 2010, 21:433-443.
3. Minkoff H., Zhong Y., Burk R., Schuman P., Klein R., Schuman P., et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in Human Immunodeficiency Virus-positive women. J Infect Dis 2010, 201:681-690.
4. Omar T., Schwartz S., Hanrahan C., Modisenyane T., Tshabangu N., Golub J., et al. Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort AIDS 2011, 25:87.
5. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
6. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632.
7. Strickler H.D., Palefsky J.M. Burk RD HPV types present in invasive cervical cancers of HIV-seropositive women. Int J Cancer 2008, 123(September (5)):1224-1225.
8. Firnhaber C.S., Zungu K., Levin S., Michelow P., Montaner L.J., Macphail P., et al. A high prevalence of high risk human papillomavirus and cervical dysplasia in HIV seropositive women in an urban South African Cervical Cancer Cohort (SACCC). Acta Cytol 2009, 53:10-18.
9. Sahasrabuddhe V.V., Mwanahamuntu M.H., Vermund S.H., Huh W.K., Lyon M.D., Stringer J.S., et al. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer 2007, 96:1480-1483.
10. Cerqueira D.M., de S Moraes D., Camara G.N., Amaral F.A., Oyama C.N., dos Santos M.Q., et al. High HPV genetic diversity in women infected with HIV-1 in Brazil. Arch Virol 2007, 152:75-83. (January).
11. Harper D., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
12. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadravalent human papillomavirus (types 6, 11, 16, and 18) L1 virus like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(5):271-278.
13. Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., Prey M., et al. The 2001 Bethesda system terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119.
14. Christensten N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996, 223:174-184.
15. Christensen N.D., Reed C.A., Cladel N.M., Hall K., Leiserowitz G.S. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 1996, 224:447-486.
16. Marias D.J., Carrara H., Ramjee G., Kay P., Williamson A.L. HIV-1 seroconversion promotes rapid changes in cervical human papillomavirus (HPV) prevalence and HPV-16 antibodies in female sex workers. J Med Virol 2009, 81:203-210.
17. Mbwana J., Viscidi R., Lyamuya E., Mhalu F., Chalamilla G., Liljequvist J.-A., et al. Prevalence of serum antibodies to human papillomavirus in patients with genital ulcer disease in an urban population of Tanzania. Sex Transm Infect 2007, 83:64-65.